PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview

Area of Science:

• Nuclear medicine
• Radiopharmaceutical therapy
• Oncology

Background:

• Auger electrons (AEs) offer highly localized energy deposition for targeted radiotoxicity.
• Short AE range has limited previous therapeutic applications.
• Poly(ADP-ribose) polymerase 1 (PARP-1) is a key target due to its proximity to DNA.

Purpose of the Study:

• To provide an updated overview of preclinical studies on AE-based theranostics.
• To highlight the development of PARP-1 targeted radiopharmaceuticals for AE therapy.
• To explore the potential of AE theranostics in various cancer types.

Main Methods:

• Review of preclinical studies on AE-based theranostics.
• Focus on radiopharmaceuticals targeting PARP-1.
• Evaluation of AE theranostic applications in specific cancers.

Main Results:

• Several PARP-1 targeted radiopharmaceuticals for AE theranostics have been developed.
• Preclinical studies show potential applications in glioblastoma, breast, prostate, ovarian, and pancreatic cancers.
• AE-based theranostics offer a promising approach for targeted radionuclide therapy.

Conclusions:

• PARP-1 targeted AE theranostics represent a significant advancement in radionuclide therapy.
• This approach holds potential for treating various solid tumors.
• Further preclinical research is warranted to optimize AE-based theranostic strategies.